Advanced Epithelial Ovarian Cancer in the Elderly

differences in prognosis. In order to address these issues, we report our experience regarding treatment and prognosis in elderly patients with. FIGO ...

0 downloads 0 Views 102KB Size

Recommend Documents

Patients with advanced epithelial ovarian cancer (EOC) should be treated with ... tumour angiogenesis, tyrosine kinase inhibitors, review. ... central role played by the key growth factors in the biology .... cediranib at 20 mg/day during chemotherap

Apr 4, 2016 - epithelial ovarian cancer is surgical staging followed by adjuvant ... The behavior of fallopian tube and primary peritoneal car- cinomas is ...

DI regimens remain investigational. ○ GOG 97. – Cisplatin/Cytoxan. – 4 vs. 8 cycles, equivalent dose .... Poor performance status. – Medical comorbidities.

Ovarian cancer is usually radiosensitive. Whole abdominal (WAR). – Microscopic disease. – 2500-3000 cGy over 4-5 weeks. Tumoricidal dose. – > 2cm.

Ovarian neoplasms consist of several histopathologic entities, and treatment depends on the specific tumor type. Epithelial ovarian cancer comprises most ma-.

Nov 27, 2017 - Paulette Mhawech-Fauceglia4, Heidi Sowter5, Dennis J. Hazelett2,**, Kate ...... Adler E, Mhawech-Fauceglia P, Gayther SA, Lawrenson.

University of Michigan, Ann Arbor, MI; Sheba Medical Center, Tel Hashomer, Israel; Assaf. Harofeh Medcl Ctr, Zerifin, Israel; Stanford University School of Medicine, ..... LLC), M Gordon (Pinnacle Oncology Hematology), N Haas (University.

Nov 2, 2015 - Epithelial ovarian cancer (EOC) is currently the most lethal .... presented a study which implicates type I collagen as a steering .... to be elucidated, with no clear answer on the in vivo source of ...... The biology of the small leuc

Oct 11, 2012 - non-seromucinous EOC, non-epithelial ovarian tumors and primary peritoneal tumors were not included in the study. All patients underwent ...

Chen, V.W., Ruiz, B., Killeen, J.L., Coté, T.R., Wu, X.C., and Correa, C.N. (2003) ...... Faleiro-Rodrigues, C., Macedo-Pinto, I., Pereira, D., and Lopes, C.S. (2004) Loss of .... Evangelista,M., Tian, H., and de Sauvage F.J. (2006) The hedgehog ...

Xiaoxi Sun,3 Youji Feng,1 Viktor Janzen,4 and Tong Chen2. 1Department of Gynecology, Obstetrics and ...... Wei X, et al. (2010) Mullerian inhibiting substance.

Nov 9, 2010 - epithelial ovarian cancers (EOC). ... cells in human tumours came from a study in acute myeloid leukemia ...... of Biological Chemistry, vol. 275 ...

and the other four used pazopanib, nintedanib, cediranib, and trebananib. Bevacizumab has gained European Medicines. Agency approval for the first-line ...

Feb 23, 2010 - Angiogenesis is essential for normal ovarian physiological ... Antiangiogenic therapies inhibit new blood vessel growth, induce ..... Common toxicities observed include fatigue, skin rash and GI toxicities, Table 4. .... need for biops

Jun 14, 2012 - that high NuMA levels at mitotic spindle poles were significantly associated with .... metaphase defects such as tripolar and multipolar spindles.

Dec 31, 2013 - antagonist, Plerixafor or AMD3100 (Anormed) [108,109]. Importantly, clinical trials evaluating efficacy of small molecule inhibitors as well as ...

Such technologies can complement well-established clinical histopathology analysis ... ciated with serous tubal intraepithelial carcinoma as a precursor ..... (A) Flowchart of the study outlining the steps for training and validating the prognostic.

and cediranib (AZD2171, Recentine, AstraZene- ca, Macclesfield, UK), are currently being under investigation7-10. Indeeds, several previous me- ta-analyses ...

Mar 8, 2016 - 1Department of Medical Oncology, Regional Cancer Centre, Thiruvananthapuram 695011, India .... Bevacizumab is a recombinant humanised monoclonal IgG ... cancer paved the way for phase-II trials testing bevacizumab in combination .... es

aggressive tumor biology, including higher grade and more advanced stage, (2) .... 10%) for 30-day mortality after CRS were those older than age 75 with stage IV .... SEER review of the use of chemotherapy in advanced EOC, the odds of ...

Ovarian cancer patients who carry germ-line BRCA1 mutations may have improved survival compared with ovarian cancer patients without these mutations.

Feb 15, 2012 - This article will review the trials that have been conducted with PARP .... MK4827 show that 10 of 12 partial responses seen were in EOC ... of veliparib given twice daily for 15 days out of a 21-day cycle while .... The need for predi

relapse after primary treatment and succumb to disease ... Keywords: TP53 mutation; epithelial ovarian cancer (EOC); biomarkers; prognosis; chemoresistance; ...

Most trials of hormonal treatment in ovarian cancer have been ... with epithelial ovarian cancer needs more thorough evaluation in well-designed randomized ...